Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study
- PMID: 26708778
- DOI: 10.1016/j.brs.2015.11.007
Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study
Abstract
Background: Repetitive transcranial magnetic stimulation (TMS) is efficacious for acute treatment of resistant major depressive disorder (MDD), but there is little information on maintenance TMS after acute response.
Objective/hypothesis: This pilot feasibility study investigated 12-month outcomes comparing two maintenance TMS approaches--a scheduled, single TMS session delivered monthly (SCH) vs. observation only (OBS).
Methods: Antidepressant-free patients with unipolar, non-psychotic, treatment-resistant MDD participated in a randomized, open-label, multisite trial. Patients meeting protocol-defined criteria for improvement after six weeks of acute TMS were randomized to SCH or OBS regimens. TMS reintroduction was available for symptomatic worsening; all patients remained antidepressant-free during the trial.
Results: Sixty-seven patients enrolled in the acute phase, and 49 (73%) met randomization criteria. Groups were matched, although more patients in the SCH group had failed ≥ 2 antidepressants (p = .035). There were no significant group differences on any outcome measure. SCH patients had nonsignificantly longer time to first TMS reintroduction, 91 ± 66 days, vs. OBS, 77 ± 52 days; OBS patients were nonsignificantly more likely to need reintroduction (odds ratio = 1.21, 95% CI .38-3.89). Reintroduction lasted 14.3 ± 17.8 days (SCH) and 16.9 ± 18.9 days (OBS); 14/18 (78%) SCH and 17/27 (63%) OBS responded to reintroduction. Sixteen patients (32.7%) completed all 53 weeks of the study.
Conclusions: Maintaining treatment-resistant depressed patients off medications with periodic TMS appears feasible in some cases. There was no statistical advantage of SCH vs. OBS, although SCH was associated with a nonsignificantly longer time to relapse. Those who initially respond to TMS have a strong chance of re-responding if relapse occurs.
Keywords: Long term outcome; Maintenance of effect; Pilot clinical trial; Transcranial magnetic stimulation.
Published by Elsevier Inc.
Similar articles
-
A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period.J Clin Psychiatry. 2014 Dec;75(12):1394-401. doi: 10.4088/JCP.13m08977. J Clin Psychiatry. 2014. PMID: 25271871
-
Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression: acute and six month outcomes.Brain Stimul. 2014 Mar-Apr;7(2):219-25. doi: 10.1016/j.brs.2013.10.008. Epub 2013 Nov 4. Brain Stimul. 2014. PMID: 24332384 Clinical Trial.
-
Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study.Brain Stimul. 2010 Oct;3(4):187-99. doi: 10.1016/j.brs.2010.07.003. Epub 2010 Aug 11. Brain Stimul. 2010. PMID: 20965447 Clinical Trial.
-
Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data.Psychopharmacol Bull. 2009;42(2):5-38. Psychopharmacol Bull. 2009. PMID: 19629020 Review.
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
Cited by
-
The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder.Brain Stimul. 2016 May-Jun;9(3):336-346. doi: 10.1016/j.brs.2016.03.010. Epub 2016 Mar 16. Brain Stimul. 2016. PMID: 27090022 Free PMC article. Review.
-
Targeted neural network interventions for auditory hallucinations: Can TMS inform DBS?Schizophr Res. 2018 May;195:455-462. doi: 10.1016/j.schres.2017.09.020. Epub 2017 Sep 29. Schizophr Res. 2018. PMID: 28969932 Free PMC article.
-
Cost effectiveness analysis comparing repetitive transcranial magnetic stimulation to antidepressant medications after a first treatment failure for major depressive disorder in newly diagnosed patients - A lifetime analysis.PLoS One. 2017 Oct 26;12(10):e0186950. doi: 10.1371/journal.pone.0186950. eCollection 2017. PLoS One. 2017. PMID: 29073256 Free PMC article.
-
Maintenance treatment of transcranial magnetic stimulation (TMS) for treatment-resistant depression patients responding to acute TMS treatment.Int J Physiol Pathophysiol Pharmacol. 2020 Oct 15;12(5):128-133. eCollection 2020. Int J Physiol Pathophysiol Pharmacol. 2020. PMID: 33224435 Free PMC article. Review.
-
Investigating the Role of Maintenance TMS Protocols for Major Depression: Systematic Review and Future Perspectives for Personalized Interventions.J Pers Med. 2023 Apr 21;13(4):697. doi: 10.3390/jpm13040697. J Pers Med. 2023. PMID: 37109083 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous